{"nctId":"NCT01234649","briefTitle":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","startDateStruct":{"date":"2011-08-11","type":"ACTUAL"},"conditions":["Gestational Diabetes Mellitus","Type 2 Diabetes Mellitus","Metabolic Syndrome","Impaired Glucose Tolerance","Disorder of Glucose Regulation"],"count":153,"armGroups":[{"label":"Metformin XR plus liraglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin XR plus liraglutide"]},{"label":"Metformin XR plus placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin XR plus placebo"]}],"interventions":[{"name":"Metformin XR plus placebo","otherNames":["Metformin XR is generic"]},{"name":"Metformin XR plus liraglutide","otherNames":["Victoza"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult female 18 years to 45 years of age who experienced GDM within 52 weeks of index pregnancy\n* Actual BMI \\>25 kg/ m2\n* Written consent for participation in the study\n* Patient completed lactation\n* Dysglycemia (impaired fasting glucose \\[IFG}, impaired glucose tolerance \\[IGT} or IFG/IGT) and/or ß-cell dysfunction postpartum requiring pharmacological intervention (except type 1 or 2 diabetes)\n\nExclusion Criteria:\n\nPersonal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n\n* History of pancreatitis\n* Significant cardiovascular, cerebrovascular, renal, or hepatobiliary diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology)\n* Serum liver enzymes (AST and/or ALT levels) exceeding more than twice normal laboratory values\n* Uncontrolled hypertension (systolic blood pressure\\>150 mm Hg and/or diastolic blood pressure \\>90 mm Hg)\n* Fasting serum triglycerides ≥800 mg/dl at screening. Lipid-lowering medications must have been maintained at the same dose for 3 months prior to enrollment\n* Hematological profiles considered to be clinically significant\n* Cholestasis during the past pregnancy\n* Presence of contradictions for GLP-1 receptor agonist or metformin administration such as allergy or hypersensitivity\n* Current use of metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors or GLP-1 receptor agonist medications.\n* Use of drugs known to exacerbate glucose tolerance.\n* Use of prescription or over-the-counter weight-loss drugs\n* Diabetes postpartum or history of diabetes or prior use of medications to treat diabetes except gestational diabetes\n* Creatinine clearance less than 60 ml/min\n* History or currently undergoing chemotherapy or radiotherapy for cancer\n* Pregnancy planned during the coming two years\n* Currently breastfeeding\n* Exclusion criteria include any condition, which in the opinion of the investigator would place the subject at increased risk or otherwise make the subject unsuitable for participation in the study","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Insulin Secretion-Sensitivity Index (IS-SI)","description":"IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"418.4","spread":"387"},{"groupId":"OG001","value":"333","spread":"206"}]}]}]},{"type":"SECONDARY","title":"Fasting Blood Glucose (FBG)","description":"Fasting glucose levels in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":"6.4"},{"groupId":"OG001","value":"91.7","spread":"8.4"}]}]}]},{"type":"SECONDARY","title":"Mean Glucose During OGTT (MBG)","description":"MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.6","spread":"20.8"},{"groupId":"OG001","value":"118.8","spread":"18.9"}]}]}]},{"type":"SECONDARY","title":"Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)","description":"HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.4"},{"groupId":"OG001","value":"2.45","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Matsuda Insulin Sensitivity Index Derived From OGTT","description":"OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"2.9"},{"groupId":"OG001","value":"5.4","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Insulinogenic Index (IGI) /HOMA-IR","description":"IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.14"},{"groupId":"OG001","value":"0.62","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Absolute Body Weight","description":"Body weight in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.2","spread":"18.6"},{"groupId":"OG001","value":"91.3","spread":"20"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to End of Study (Expressed as % Compared to Baseline)","description":"Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"1.3"},{"groupId":"OG001","value":"-3.1","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Body Mass Index (BMI)","description":"BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8","spread":"5.2"},{"groupId":"OG001","value":"32.8","spread":"6"}]}]}]},{"type":"SECONDARY","title":"Waist Circumference (WC)","description":"Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":"15.2"},{"groupId":"OG001","value":"95.3","spread":"15.2"}]}]}]},{"type":"SECONDARY","title":"Waist-to-Hip Ratio (WHR)","description":"Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".81","spread":".04"},{"groupId":"OG001","value":".81","spread":".05"}]}]}]},{"type":"SECONDARY","title":"Waist to Height Ratio (WHtR)","description":"Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".56","spread":".08"},{"groupId":"OG001","value":".57","spread":".07"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol (CHOL) Levels","description":"CHOL levels in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"183.7","spread":"36"},{"groupId":"OG001","value":"183.8","spread":"27"}]}]}]},{"type":"SECONDARY","title":"High Density Lipoprotein Cholesterol (HDL-C) Levels","description":"HDL-C levels in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":"12.6"},{"groupId":"OG001","value":"48.7","spread":"11.7"}]}]}]},{"type":"SECONDARY","title":"Low Density Lipoprotein Cholesterol (LDL-C) Levels","description":"LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":"32"},{"groupId":"OG001","value":"107","spread":"25"}]}]}]},{"type":"SECONDARY","title":"Triglyceride (TRG) Levels","description":"TRG concentrations in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":"64.5"},{"groupId":"OG001","value":"125","spread":"76.4"}]}]}]},{"type":"SECONDARY","title":"Triglyceride to High Density Lipoprotein Cholesterol Ratio TRG/HDL-C)","description":"TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","spread":"1.5"},{"groupId":"OG001","value":"2.95","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure","description":"SBP in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":"12"},{"groupId":"OG001","value":"123","spread":"12"}]}]}]},{"type":"SECONDARY","title":"Diastolic Blood Pressure","description":"DBP in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":"8.9"},{"groupId":"OG001","value":"77","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Alanine Aminotransferase (ALT) Levels","description":"Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"10.7"},{"groupId":"OG001","value":"31","spread":"9.9"}]}]}]},{"type":"SECONDARY","title":"Aspartate Aminotransferase (AST)","description":"The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":"8"},{"groupId":"OG001","value":"28","spread":"10.5"}]}]}]},{"type":"SECONDARY","title":"Alanine Aminotransferase /Aspartate Aminotransferase (ALT/AST) Ratio","description":"ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.4"},{"groupId":"OG001","value":"1.18","spread":"0.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Nausea","Diarrhea","Allergic reaction to liraglutide"]}}}